Cystic fibrosis and diabetes link explained

Cystic fibrosis
"Clubbing" of the fingers is a classic features of Cystic Fibrosis, although not present in many patients. Credit: Jerry Nick, M.D./ Wikipedia

Many people with cystic fibrosis develop diabetes. The reasons for this have been largely unknown, but now researchers at Lund University in Sweden and Karolinska institutet have identified a molecular mechanism that contributes to the raised diabetes risk.

"The increased risk of diabetes has previously been explained by the fact that causes damage to the pancreas, where the blood-sugar regulating
 is produced. We are the first research group to show that the mutated gene that causes cystic fibrosis also plays an important role in the release of insulin. The risk of diabetes is not only explained by the destruction of the pancreas", said Anna Edlund, a doctoral student at Lund University Diabetes Centre.

Cystic fibrosis is the result of a genetic mutation in an ion channel that normally regulates salt transport in cells, primarily in the lungs and pancreas. The mutation leads to a wide variety of symptoms. Individuals with cystic fibrosis produce a lot of thick, viscous mucus. This makes their airways sensitive to infection, and repeated or chronic lung infections are common. The secretion of pancreatic juice from the pancreas to the intestine is hindered, which causes diarrhoea and poor weight gain.

Left untreated, cystic fibrosis is fatal, but with improved treatment of symptoms, survival has improved. Many people with cystic fibrosis now live beyond the age of 40.

"Cystic Fibrosis is a severe health condition and diabetes exacerbates an already problematic situation", said Malin Flodström-Tullberg, a researcher at the Centre for Infectious Medicine, Karolinska institutet.

Many people with cystic fibrosis have poor sugar metabolism. At the age of 30, around one in four people with cystic fibrosis
also has diabetes that requires treatment with insulin. What the researchers have now shown is that the mutation in the cystic fibrosis gene inhibits the secretion of insulin into the blood, which means that the level is insufficient
when the demands on the insulin increase, such as after a meal.

"Normally, insulin is released in two stages. The early stage is a rapid response to raised blood sugar and the later stage aims to restore blood sugar levels. In cystic fibrosis, the early stage of in particular is insufficient", said Anna Edlund, adding:

"Our results also correspond to clinical observations. Many patients with cystic fibrosis who do not have diabetes have normal blood sugar in a fasting state, but raised after a meal."

The researchers have worked on insulin producing cells from mice and deceased donors. They have shown that the cystic fibrosis gene plays an important role
in the complex chain of events that precedes the release of insulin.

When the cells were exposed to high glucose levels, they responded as expected by increasing , but when a preparation that specifically
obstructs the expressed by the cystic fibrosis gene was added, the cells' ability to release insulin fell significantly.

"Despite being common among , surprisingly little is known about the mechanisms behind in this group of individuals. We
need to know what causes the problem in order to develop preventive treatments that improve the cells' ability to secrete insulin. Our study provide a first
piece of increased understanding how CFTR contribute to secretion", said Lena Eliasson, Professor at Lund University Diabetes Centre.

More information: Anna Edlund, Jonathan LS Esguerra, Anna Wendt, Malin Flodström-Tullberg and Lena Eliasson. "CFTR and Anoctamin 1 (ANO1) contribute to cAMP amplified exocytosis and insulin secretion in human and murine pancreatic beta-cells." BMC Medicine. DOI: 10.1186/1741-7015-12-87

Journal information: BMC Medicine
Provided by Lund University
Citation: Cystic fibrosis and diabetes link explained (2014, June 2) retrieved 19 April 2024 from https://medicalxpress.com/news/2014-06-cystic-fibrosis-diabetes-link.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Inhaler approved for cystic fibrosis patients

 shares

Feedback to editors